These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38522155)

  • 1. Leishmania and HIV co-infection: first naturally Leishmania strain presenting decreased susceptibility to miltefosine, recovered from a patient in Portugal.
    Pinto AI; Caldas C; Santarém N; Luelmo S; Costa I; Martins C; Monteiro R; Conde S; Tavares R; da Silva AC
    J Infect Public Health; 2024 May; 17(5):810-818. PubMed ID: 38522155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
    Faucher JF; Morquin D; Reynes J; Chirouze C; Hoen B; Le Moing V
    Parasitol Int; 2016 Oct; 65(5 Pt A):444-6. PubMed ID: 27353022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmania-human immunodeficiency virus coinfection in the Mediterranean basin: isoenzymatic characterization of 100 isolates of the Leishmania infantum complex.
    Pratlong F; Dedet JP; Marty P; Portús M; Deniau M; Dereure J; Abranches P; Reynes J; Martini A; Lefebvre M
    J Infect Dis; 1995 Jul; 172(1):323-6. PubMed ID: 7797943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Miltefosine-Lopinavir Combination Therapy Against
    Rebello KM; Andrade-Neto VV; Gomes CRB; de Souza MVN; Branquinha MH; Santos ALS; Torres-Santos EC; d'Avila-Levy CM
    Front Cell Infect Microbiol; 2019; 9():229. PubMed ID: 31316919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High frequency of subclinical Leishmania infection among HIV-infected patients living in the endemic areas of visceral leishmaniasis in Fars province, southern Iran.
    Rezaei Z; Sarkari B; Dehghani M; Layegh Gigloo A; Afrashteh M
    Parasitol Res; 2018 Aug; 117(8):2591-2595. PubMed ID: 29860572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic High-Level Parasitemia in HIV-Infected Individuals With or Without Visceral Leishmaniasis in an Endemic Area in Northwest Ethiopia: Potential Superspreaders?
    van Griensven J; van Henten S; Kibret A; Kassa M; Beyene H; Abdellati S; de Hondt A; Adriaensen W; Vogt F; Pareyn M; Ritmeijer K; Diro E
    Clin Infect Dis; 2024 Jul; 79(1):240-246. PubMed ID: 38193647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
    Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic analysis of the soluble proteomes of miltefosine-sensitive and -resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes.
    Carnielli JB; de Andrade HM; Pires SF; Chapeaurouge AD; Perales J; Monti-Rocha R; Carvalho SF; Ribeiro LP; Dietze R; Figueiredo SG; Lemos EM
    J Proteomics; 2014 Aug; 108():198-208. PubMed ID: 24874972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Following successful anti-leishmanial treatment, neutrophil counts, CD10 expression and phagocytic capacity remain reduced in visceral leishmaniasis patients co-infected with HIV.
    Takele Y; Adem E; Mulaw T; Müller I; Cotton JA; Kropf P
    PLoS Negl Trop Dis; 2022 Aug; 16(8):e0010681. PubMed ID: 35969625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts.
    Kubar J; Marty P; Lelièvre A; Quaranta JF; Staccini P; Caroli-Bosc C; Le Fichoux Y
    AIDS; 1998 Nov; 12(16):2147-53. PubMed ID: 9833855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
    Reimão JQ; Pita Pedro DP; Coelho AC
    Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil.
    Dos Santos Nogueira F; Avino VC; Galvis-Ovallos F; Pereira-Chioccola VL; Moreira MAB; Romariz APPL; Molla LM; Menz I
    Parasit Vectors; 2019 Feb; 12(1):79. PubMed ID: 30736866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis.
    Carnielli JBT; Crouch K; Forrester S; Silva VC; Carvalho SFG; Damasceno JD; Brown E; Dickens NJ; Costa DL; Costa CHN; Dietze R; Jeffares DC; Mottram JC
    EBioMedicine; 2018 Oct; 36():83-91. PubMed ID: 30268832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antileishmanial activity of antiretroviral drugs combined with miltefosine.
    Costa S; Machado M; Cavadas C; do Céu Sousa M
    Parasitol Res; 2016 Oct; 115(10):3881-7. PubMed ID: 27249967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
    Maia C; Nunes M; Marques M; Henriques S; Rolão N; Campino L
    Exp Parasitol; 2013 Sep; 135(1):36-41. PubMed ID: 23747751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired Thymic Output Can Be Related to the Low Immune Reconstitution and T Cell Repertoire Disturbances in Relapsing Visceral Leishmaniasis Associated HIV/AIDS Patients.
    Silva-Freitas ML; Corrêa-Castro G; Cota GF; Giacoia-Gripp C; Rabello A; Teixeira Dutra J; de Vasconcelos ZFM; Savino W; Da-Cruz AM; Santos-Oliveira JR
    Front Immunol; 2020; 11():953. PubMed ID: 32508833
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical aspects of visceral leishmaniasis caused by L. infantum in adults. Ten years of experience of the largest outbreak in Europe: what have we learned?
    Horrillo L; Castro A; Matía B; Molina L; García-Martínez J; Jaqueti J; García-Arata I; Carrillo E; Moreno J; Ruiz-Giardin JM; San Martín J
    Parasit Vectors; 2019 Jul; 12(1):359. PubMed ID: 31340851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphoproliferative response after stimulation with soluble leishmania antigen (SLA) as a predictor of visceral leishmaniasis (VL) relapse in HIV+ patients.
    Castro A; Carrillo E; San Martín JV; Botana L; Molina L; Matía B; Fernandez L; Horrillo L; Ibarra-Meneses A; Sanchez C; Ruiz-Giardin JM; Moreno J
    Acta Trop; 2016 Dec; 164():345-351. PubMed ID: 27693332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbial translocation induces an intense proinflammatory response in patients with visceral leishmaniasis and HIV type 1 coinfection.
    Santos-Oliveira JR; Regis EG; Giacoia-Gripp CB; Valverde JG; Alexandrino-de-Oliveira P; Lindoso JÂ; Goto H; Oliveira-Neto MP; Guerra JO; Grinsztejn B; Jerônimo SB; Morgado MG; Da-Cruz AM
    J Infect Dis; 2013 Jul; 208(1):57-66. PubMed ID: 23539743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.